Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Next Previous
Search
Trial Profile

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs [177Lu]Lu NNS309 (Primary) ; [68Ga]Ga NNS309 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 19 Dec 2024 According to a PeptiDream, Novartis media release, company announced initiation of this study.
    • 06 Dec 2024 Planned primary completion date changed from 26 Jun 2030 to 25 Jun 2030.
    • 30 Sep 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top